Shenzhen Neptunus Bioengineering Co Ltd (000078) - Net Assets
Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) has net assets worth CN¥2.16 Billion CNY (≈ $315.45 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥25.73 Billion ≈ $3.77 Billion USD) and total liabilities (CN¥23.58 Billion ≈ $3.45 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Shenzhen Neptunus Bioengineering Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.16 Billion |
| % of Total Assets | 8.38% |
| Annual Growth Rate | 13.24% |
| 5-Year Change | -70.22% |
| 10-Year Change | -62.97% |
| Growth Volatility | 138.36 |
Shenzhen Neptunus Bioengineering Co Ltd - Net Assets Trend (1995–2025)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Shenzhen Neptunus Bioengineering Co Ltd to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shenzhen Neptunus Bioengineering Co Ltd (1995–2025)
The table below shows the annual net assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2025. For live valuation and market cap data, see 000078 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.18 Billion ≈ $318.49 Million |
-23.46% |
| 2024-12-31 | CN¥2.84 Billion ≈ $416.13 Million |
-32.57% |
| 2023-12-31 | CN¥4.22 Billion ≈ $617.14 Million |
-30.98% |
| 2022-12-31 | CN¥6.11 Billion ≈ $894.15 Million |
-16.39% |
| 2021-12-31 | CN¥7.31 Billion ≈ $1.07 Billion |
-2.42% |
| 2020-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
-4.60% |
| 2019-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
+9.67% |
| 2018-12-31 | CN¥7.16 Billion ≈ $1.05 Billion |
+10.64% |
| 2017-12-31 | CN¥6.47 Billion ≈ $946.76 Million |
+10.07% |
| 2016-12-31 | CN¥5.88 Billion ≈ $860.13 Million |
+174.28% |
| 2015-12-31 | CN¥2.14 Billion ≈ $313.60 Million |
+20.22% |
| 2014-12-31 | CN¥1.78 Billion ≈ $260.85 Million |
-5.58% |
| 2013-12-31 | CN¥1.89 Billion ≈ $276.27 Million |
+78.62% |
| 2012-12-31 | CN¥1.06 Billion ≈ $154.67 Million |
+8.85% |
| 2011-12-31 | CN¥971.04 Million ≈ $142.09 Million |
+7.58% |
| 2010-12-31 | CN¥902.62 Million ≈ $132.08 Million |
+30.33% |
| 2009-12-31 | CN¥692.59 Million ≈ $101.35 Million |
-11.30% |
| 2008-12-31 | CN¥780.79 Million ≈ $114.25 Million |
-13.59% |
| 2007-12-31 | CN¥903.62 Million ≈ $132.23 Million |
+4.01% |
| 2006-12-31 | CN¥868.76 Million ≈ $127.13 Million |
+7.89% |
| 2005-12-31 | CN¥805.26 Million ≈ $117.83 Million |
-44.54% |
| 2004-12-31 | CN¥1.45 Billion ≈ $212.47 Million |
+0.59% |
| 2003-12-31 | CN¥1.44 Billion ≈ $211.22 Million |
-30.04% |
| 2002-12-31 | CN¥2.06 Billion ≈ $301.91 Million |
+4.48% |
| 2001-12-31 | CN¥1.97 Billion ≈ $288.97 Million |
+727.14% |
| 2000-12-31 | CN¥238.75 Million ≈ $34.94 Million |
+16.07% |
| 1999-12-31 | CN¥205.69 Million ≈ $30.10 Million |
+16.16% |
| 1998-12-31 | CN¥177.08 Million ≈ $25.91 Million |
+207.28% |
| 1997-12-31 | CN¥57.63 Million ≈ $8.43 Million |
+2.64% |
| 1996-12-31 | CN¥56.14 Million ≈ $8.22 Million |
+7.65% |
| 1995-12-31 | CN¥52.15 Million ≈ $7.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Neptunus Bioengineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 348709213032.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥4.71 Billion | 384.17% |
| Total Equity | CN¥1.23 Billion | 100.00% |
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Market Cap
The table below lists competitors of Shenzhen Neptunus Bioengineering Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rio2 Ltd
V:RIO
|
$566.25 Million |
|
Fireweed Zinc Ltd
V:FWZ
|
$566.36 Million |
|
Legacy Housing Corp
NASDAQ:LEGH
|
$566.72 Million |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
|
$566.74 Million |
|
Standard Chartered PLC
LSE:STAN
|
$565.80 Million |
|
Beijing Jingcheng Machinery Electric Co Ltd
SHG:600860
|
$565.76 Million |
|
Tilray Inc
NASDAQ:TLRY
|
$565.73 Million |
|
ChongQing Zhengchuan Pharmaceutical Packaging Co Ltd
SHG:603976
|
$565.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Neptunus Bioengineering Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,795,232,448 to 1,227,113,526, a change of -568,118,922 (-31.6%).
- Net loss of 563,060,359 reduced equity.
- Dividend payments of 513,154,249 reduced retained earnings.
- Other comprehensive income decreased equity by 135,556,112.
- Other factors increased equity by 643,651,799.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-563.06 Million | -45.88% |
| Dividends Paid | CN¥513.15 Million | -41.82% |
| Other Comprehensive Income | CN¥-135.56 Million | -11.05% |
| Other Changes | CN¥643.65 Million | +52.45% |
| Total Change | CN¥- | -31.65% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Neptunus Bioengineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 43.82x to 3.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | CN¥0.03 | CN¥1.47 | x |
| 1996-12-31 | CN¥0.04 | CN¥1.47 | x |
| 1997-12-31 | CN¥0.04 | CN¥1.47 | x |
| 1998-12-31 | CN¥0.11 | CN¥1.47 | x |
| 1999-12-31 | CN¥0.13 | CN¥1.47 | x |
| 2000-12-31 | CN¥0.15 | CN¥1.47 | x |
| 2001-12-31 | CN¥1.08 | CN¥1.47 | x |
| 2002-12-31 | CN¥0.77 | CN¥1.47 | x |
| 2003-12-31 | CN¥0.65 | CN¥1.47 | x |
| 2004-12-31 | CN¥0.64 | CN¥1.47 | x |
| 2005-12-31 | CN¥0.32 | CN¥1.47 | x |
| 2006-12-31 | CN¥0.46 | CN¥1.47 | x |
| 2007-12-31 | CN¥0.46 | CN¥1.47 | x |
| 2008-12-31 | CN¥0.43 | CN¥1.47 | x |
| 2009-12-31 | CN¥0.39 | CN¥1.47 | x |
| 2010-12-31 | CN¥0.45 | CN¥1.47 | x |
| 2011-12-31 | CN¥0.49 | CN¥1.47 | x |
| 2012-12-31 | CN¥0.52 | CN¥1.47 | x |
| 2013-12-31 | CN¥0.86 | CN¥1.47 | x |
| 2014-12-31 | CN¥0.79 | CN¥1.47 | x |
| 2015-12-31 | CN¥0.98 | CN¥1.47 | x |
| 2016-12-31 | CN¥2.41 | CN¥1.47 | x |
| 2017-12-31 | CN¥2.10 | CN¥1.47 | x |
| 2018-12-31 | CN¥2.25 | CN¥1.47 | x |
| 2019-12-31 | CN¥2.36 | CN¥1.47 | x |
| 2020-12-31 | CN¥2.24 | CN¥1.47 | x |
| 2021-12-31 | CN¥2.22 | CN¥1.47 | x |
| 2022-12-31 | CN¥1.78 | CN¥1.47 | x |
| 2023-12-31 | CN¥1.14 | CN¥1.47 | x |
| 2024-12-31 | CN¥0.68 | CN¥1.47 | x |
| 2025-12-31 | CN¥0.47 | CN¥1.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Neptunus Bioengineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.11%
- • Asset Turnover: 1.01x
- • Equity Multiplier: 21.46x
- Recent ROE (-45.88%) is below the historical average (-2.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 21.94% | 22.82% | 0.60x | 1.59x | CN¥6.19 Million |
| 1996 | 31.19% | 21.85% | 0.63x | 2.26x | CN¥11.55 Million |
| 1997 | 31.69% | 28.97% | 0.43x | 2.54x | CN¥12.43 Million |
| 1998 | 14.83% | 40.56% | 0.28x | 1.30x | CN¥8.52 Million |
| 1999 | 15.17% | 35.15% | 0.14x | 3.14x | CN¥10.59 Million |
| 2000 | 26.11% | 30.92% | 0.23x | 3.70x | CN¥37.96 Million |
| 2001 | 4.79% | 10.43% | 0.25x | 1.83x | CN¥-86.83 Million |
| 2002 | 2.50% | 5.09% | 0.24x | 2.03x | CN¥-126.79 Million |
| 2003 | -15.60% | -17.16% | 0.32x | 2.86x | CN¥-360.99 Million |
| 2004 | 1.58% | 0.95% | 0.62x | 2.67x | CN¥-117.57 Million |
| 2005 | -107.62% | -27.91% | 0.67x | 5.78x | CN¥-810.82 Million |
| 2006 | 5.93% | 1.58% | 0.76x | 4.92x | CN¥-29.16 Million |
| 2007 | 5.17% | 1.55% | 0.80x | 4.17x | CN¥-36.11 Million |
| 2008 | 3.46% | 1.10% | 0.80x | 3.95x | CN¥-46.02 Million |
| 2009 | 2.25% | 0.52% | 0.86x | 5.03x | CN¥-48.79 Million |
| 2010 | 6.29% | 1.17% | 0.96x | 5.59x | CN¥-27.50 Million |
| 2011 | 6.63% | 0.99% | 1.10x | 6.11x | CN¥-26.65 Million |
| 2012 | 7.00% | 0.92% | 1.09x | 6.95x | CN¥-25.27 Million |
| 2013 | 7.69% | 1.46% | 1.00x | 5.27x | CN¥-35.19 Million |
| 2014 | 1.65% | 0.24% | 1.02x | 6.70x | CN¥-120.00 Million |
| 2015 | 26.31% | 4.27% | 0.87x | 7.07x | CN¥294.29 Million |
| 2016 | 7.80% | 3.08% | 0.82x | 3.10x | CN¥-118.21 Million |
| 2017 | 11.53% | 2.55% | 0.81x | 5.59x | CN¥84.66 Million |
| 2018 | 6.93% | 1.08% | 0.93x | 6.87x | CN¥-183.61 Million |
| 2019 | 3.30% | 0.50% | 1.01x | 6.58x | CN¥-419.22 Million |
| 2020 | -4.91% | -0.72% | 1.01x | 6.76x | CN¥-876.41 Million |
| 2021 | 1.60% | 0.23% | 1.09x | 6.46x | CN¥-488.92 Million |
| 2022 | -21.89% | -2.71% | 1.04x | 7.73x | CN¥-1.50 Billion |
| 2023 | -56.28% | -4.64% | 1.13x | 10.76x | CN¥-1.99 Billion |
| 2024 | -66.48% | -3.94% | 1.05x | 16.04x | CN¥-1.37 Billion |
| 2025 | -45.88% | -2.11% | 1.01x | 21.46x | CN¥-685.77 Million |
Industry Comparison
This section compares Shenzhen Neptunus Bioengineering Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,817,235,327
- Average return on equity (ROE) among peers: 4.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | CN¥2.16 Billion | 21.94% | 10.94x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more